SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?


To: JGoren who wrote (2503)12/14/1999 3:12:00 PM
From: JGoren  Respond to of 2539
 
Grower Surveys Indicate Positive Intentions to Plant Biotech Crops in 2000,Monsanto Says


ST. LOUIS, Dec. 14 /PRNewswire/ -- Grower intentions to plant biotechnology-improved crops in 2000 are on track compared to intentions at this time one year ago for the 1999 crop season, according to a recently completed survey of more than 2,000 U.S. growers. In addition, the surveys suggested that the number of growers intending to plant conventional varieties in 2000 has not changed significantly over 1999.

Ninety-seven percent of U.S. soybean growers who planted Roundup Ready soybeans in 1999 were very or somewhat satisfied with the results, according to the results of another survey of nearly 900 growers. Both studies were conducted by Marketing Horizons during and after harvest.

"Farmers told us they value the benefits that biotechnology provides as they consider their planting intentions for 2000. Biotechnology allows greater flexibility, more effective insect and weed control, reduced input costs pertaining to the reduction of pesticides, improved yield potential, higher quality grain and cost savings," said Brett Begemann, vice president, U.S. markets.

Ninety-two percent of growers surveyed who planted Roundup Ready corn said they were very or somewhat satisfied with improved crops/trait performance; 83 percent of YieldGard corn growers said they were very or somewhat satisfied; and 92 percent of cotton growers who planted Roundup Ready cotton in 1999 said they were very or somewhat satisfied with the crop performance. Seventy-nine percent of growers planting Bollgard cotton indicated that they were very or somewhat satisfied.

"Until the seeds are in the ground, it is hard to speculate what the market might look like," Begemann said. "But we are already seeing solid evidence from surveys and grain trader announcements that indicate to us that the biotech growth trend will continue. For example, the actual acreage of Roundup Ready soybeans planted in l999 was significantly more than what was projected by a preseason survey. In fact, 20 percent more acres were actually planted than indicated by those November l998 survey results."

Reuters reported last week that Cargill Inc., in response to marketplace concerns, reaffirmed that it will accept biotech soybeans and corn, with no price penalty, for crops planted in 1999 and 2000 that have been approved for use in the United States and major import markets, including Europe. For more information, see cargill.com . "This announcement from the world's largest exporter of grain is welcome news to growers who choose to plant and market biotech varieties," Begemann said.

Roundup Ready soybeans and corn are genetically improved to be tolerant to over-the-top applications of Roundup Ultra herbicide, thereby providing effective post-emergent weed control. YieldGard corn provides season-long insect protection from European and Southwestern corn borer, thereby reducing reliance on chemical insecticides to control pests. This can save growers both time and money. According to survey results, U.S. growers say they value the Roundup Ready soybean system for its flexible weed control, cost-savings and convenience.

Wayne McMannus of Vincent, Iowa, a first-time user of YieldGard corn this year, said a bottom-line return was necessary in order for him to invest in biotech crops. "YieldGard corn has an advantage because even if we have a low infestation of corn borers like last year, we still have better stalk quality, which allows me more time to combine," he said. "I think there's an advantage, and I'm moving toward planting more next year."

Ron Heck, who farms 3,000 soybean and corn acres in Boone County, Iowa, uses data gathered from five years of site-specific farming practices to measure the profitability of his Roundup Ready soybeans. "Roundup Ready soybeans give me better weed control with less spraying," he said. "That means I spend less time in the field and more time at home with my family. Why would I give up that value?"

Ron Small, who farms 11,000 corn and soybean acres near Monroe City, Ind., said Roundup technology is more cost-effective in problem fields due to fewer chemical applications. "I've found in soybeans that we're approximately $20 per acre cheaper with the Roundup Ready weed control. And, in corn, it's probably in the range of $10 an acre cheaper than conventional," he said.

Dr. Richard Fawcett, a consultant and former weed science professor at Iowa State University, studied the benefits of Roundup Ready soybeans and made these conclusions. The soybeans, he says, bring a

-- 10 to 20 percent reduction in farm production costs;

-- 5 percent increase in yield;

-- 33 percent reduction in grain foreign matter;

-- 20 to 40 percent reduction in fuel use; and

-- 90 percent reduction in soil erosion with no-till adoption.

As a life sciences company, Monsanto is committed to finding solutions to the growing global needs for food and health by sharing common forms of science and technology among agriculture, nutrition and health. The company's 30,200 employees worldwide make and market high-value agricultural products, pharmaceuticals and food ingredients.

SOURCE Monsanto Company

CO: Monsanto Company

ST: Missouri, Illinois, Indiana

IN: CHM

SU:

12/14/1999 12:09 EST prnewswire.com



To: JGoren who wrote (2503)12/14/1999 3:13:00 PM
From: JGoren  Read Replies (1) | Respond to of 2539
 
Monsanto Seeks Panel Support for Celebrex Cancer Use


Washington, Dec. 14 (Bloomberg) -- Monsanto Co. told a U.S. government panel that its blockbuster painkiller Celebrex also holds benefit for people with a rare genetic disease that leads to colon cancer.

The advisory panel for the U.S. Food and Drug Administration is weighing Monsanto's application to market Celebrex for a hereditary condition in which large numbers of polyps grow in the colon and intestine. The polyps place sufferers at high risk for colorectal cancer.

The market for the disease is small, analysts said. Still, a panel recommendation and FDA approval for the new use of Celebrex -- which has had generated more than $1 billion in sales this year -- would provide an endorsement of the anti-cancer potential of anti-inflammatory drugs like Celebrex, the company and analysts said.

''This would be an important step,'' Tom Brakel, an analyst at Mehta Partners said before the panel met.

Monsanto shares fell 1 1/2 to 40 5/8 in early afternoon trading.

'Consistent Improvement'

Monsanto is seeking FDA clearance for Celebrex use in treating familial adenomatous polyposis, or FAP, which affects about one in every 10,000 people. There are currently no drug treatments for what researchers called an ''uncommon but devastating disease.''

Untreated, 90 percent of people with FAP will contract cancer by age 50, and the average age of death for people with FAP is 42. Current therapies are limited to surgeries such as removal of polyps or of the entire colon.

Scientists told the panel that 400 mg of Celebrex, twice-a- day, reduced the number and size of the dangerous polyps in FAP patients who took the drug for six months.

''We saw a profound reduction in the number of adenomas (or polyps) throughout the colorectum,'' said Ernest Hawk, chief of gastrointestinal and other cancer research in the division of cancer prevention at the National Cancer Institute, who presented data studies of Celebrex. ''All the analyses confirm a significant, substantial and consistent improvement.''

The National Cancer Institute collaborated with Monsanto in planning and running the study.

The panel will vote on a recommendation later today, after hearing an FDA review of the data. The agency generally follows the advice of its expert committees.

FDA Questions

To win the panel's support, Monsanto will have to overcome questions about the importance of its findings.

The research tracked polyps found in the rectum, and in a portion of the intestine called the duodenum. While Celebrex seemed to have an impact on rectal polyps, the study showed no statistically significant improvement in the condition of the duodenum, the FDA said.

Coupled with the small size of the six-month long study, which looked at 83 patients, the duodenal findings raised FDA questions, in its written guidance to the panel, as to whether the company had proven enough benefit. In discussion this morning, panel members asked why the company hadn't done a larger trial which might have answered these questions.

''Why did you content yourselves with just a two-center trial and with potentially keeping the numbers (of patients) down, when you could have gone to several centers and potentially doubled your numbers,'' said Derek Raghavan, acting chairman of the panel and the head of medical oncology at the University of Southern California's Norris Comprehensive Cancer Center.

Monsanto officials said the disease was so rare that a big study was hard to do, but said it plans a larger study to show the drug's long term anticancer effects, if the new use is approved.

Scientists have long thought that older pain drugs such as aspirin might play a role in preventing some kinds of cancer. Risks of older non-steroidal anti-inflammatory drugs though have precluded their use in the high doses which may be necessary to have an impact on cancerous conditions.

Merck & Co., which markets Vioxx, a drug from the same class as Celebrex, is also studying its drug for use in cancer.

Dec/14/1999 13:21